Drugging Cancers Big Four
What does it mean to drug cancer’s “big four”? Learn how Darryl McConnell & his team are tackling one of the biggest scientific conundrums.
Search
Our Approach
We are driven by the desire to improve human and animal health -– now and in the future. Therefore, we have developed our framework: Sustainable Development – For Generations.
EFPIA disclosure
.
Heart Failure
Heart Failure
More Green Overview
Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
All the same, yet different – Ethnic Equality Month
Mohammed Samy, Human Pharma Marketing Team Lead from Amsterdam explains how ethnic diversity creates collective strength and sustainable growth
Our Curiosity Never Stops
Dr. Cornelia Dorner-Ciossek shares her thoughts on the future of brain disease research.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Congress Patient Benefit
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
First hospital uae and gcc receive international award stroke management
Ibrahim Bin Hamad Obaidullah Hospital Receives the Diamond Award from the World Stroke Organization
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
Keep water clean
Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
Is artificial intelligence the future of farming?
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Our Partnering Culture
We embrace the power of partnerships and alliances to find even more breakthrough therapies that change lives.
New approaches in the battle against heartworm disease
Heartworm disease is a concern to dog and cat owners worldwide. Current disease control methods are increasingly challenged by drug resistance. We explore the potential for novel treatments and vaccines based on new knowledge and technology.
Bringing Precision to Psychiatry
Dr. Hugh Marston and Dr. Vikas Mohan Sharma discuss how precision psychiatry can enable people living with mental health conditions to thrive.
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Generalized pustular psoriasis at EADV
Dr. Emmanuelle Clerisme-Beaty reflects on the latest developments for generalized pustular psoriasis at this year’s virtual EADV congress
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Stem cells a new frontier
Stem cells may be a game changer for the development of new veterinary treatments. Read this story to find out why.
The Research Process
The Research Process
COVID-19 IMI2–Call 21
CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
It is about saving lives Alexis Jaliquias feline blood bank
Veterinarian Alexis Jaliquias founded one of the first blood banks for cats in South America
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.